4QR4
Brd4 Bromodomain 1 complex with its novel inhibitors
4QR4 の概要
| エントリーDOI | 10.2210/pdb4qr4/pdb |
| 関連するPDBエントリー | 4QR3 4QR5 |
| 分子名称 | Bromodomain-containing protein 4, 2-chloro-N-cyclopentyl-5-(2-oxo-2,3-dihydro-1,3-thiazol-4-yl)benzenesulfonamide (3 entities in total) |
| 機能のキーワード | brd4, bromodomain, four alpha helices, transcription-transcription inhibitor complex, transcription/transcription inhibitor |
| 由来する生物種 | Homo sapiens (human) |
| 細胞内の位置 | Nucleus: O60885 |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 15200.02 |
| 構造登録者 | |
| 主引用文献 | Zhao, L.,Wang, Y.,Cao, D.Y.,Chen, T.T.,Wang, Q.,Li, Y.,Xu, Y.C.,Zhang, N.,Wang, X.,Chen, D.,Chen, L.,Chen, Y.L.,Xia, G.,Shi, Z.,Liu, Y.C.,Lin, Y.,Miao, Z.,Shen, J.,Xiong, B. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization J.Med.Chem., 58:1281-1297, 2015 Cited by PubMed Abstract: The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by crystal structure analysis, we reversed the sulfonamide group and identified a new binding mode. A structure-activity relationship study on this new series led to several potent BRD4 inhibitors with IC50 of about 0.05-0.1 μM in FP binding assay and GI50 of 0.1-0.3 μM in cell based assays. To complete the lead-like assessment of this series, we further checked its effects on BRD4 downstream protein c-Myc, investigated its selectivity among five different bromodomain proteins, as well as the metabolic stability test, and reinforced the utility of 2-thiazolidinone scaffold as BET bromodomain inhibitors in novel anticancer drug development. PubMed: 25559428DOI: 10.1021/jm501504k 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.28 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






